Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
Titel:
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
Auteur:
Hakim, James G Thompson, Jennifer Kityo, Cissy Hoppe, Anne Kambugu, Andrew van Oosterhout, Joep J Lugemwa, Abbas Siika, Abraham Mwebaze, Raymond Mweemba, Aggrey Abongomera, George Thomason, Margaret J Easterbrook, Philippa Mugyenyi, Peter Walker, A Sarah Paton, Nicholas I
Verschenen in:
The lancet infectious diseases
Paginering:
Jaargang 18 () nr. 1 pagina's 47-57
Jaar:
2018
Inhoud:
Uitgever:
The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license